The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women
- PMID: 7551659
- DOI: 10.1093/rheumatology/34.8.742
The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women
Abstract
The aim of our study was to assess bone mineral density (BMD) in pre-menopausal women with systemic lupus erythematosus (SLE) and the influence of disease activity and use of corticosteroids. Lumbar and femoral BMD were measured in 43 patients with SLE (28 on regular steroid therapy, 15 with recent onset, non-treated) and compared with 43 healthy women matched for age. In addition, 21 SLE patients treated with corticosteroids were followed-up with a mean of 36.6 +/- 12.7 months. BMD was significantly lower in SLE patients with prednisone doses > or = 7.5 mg/day than those of recent onset (lumbar: 1.07 +/- 0.11 vs 1.15 +/- 0.13, P = 0.039; femur: 0.85 +/- 0.13 vs 0.98 +/- 0.21, P = 0.034) and the control group (lumbar: 1.07 +/- 0.11 vs 1.13 +/- 0.10, P = 0.040; femur: 0.85 +/- 0.13 vs 0.93 +/- 0.10, P = 0.028). In addition, 18% of SLE steroid users had osteoporosis. Lumbar and femoral BMD were inversely correlated with the time of treatment and the cumulative doses of prednisone. There were no significant BMD changes during the 3-yr follow-up period. In conclusion, in SLE pre-menopausal patients lumbar and femoral BMD is decreased and related to long-term corticosteroid therapy.
Similar articles
-
Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids.Br J Rheumatol. 1998 Apr;37(4):405-10. doi: 10.1093/rheumatology/37.4.405. Br J Rheumatol. 1998. PMID: 9619891
-
Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasmatic estradiol and immunosuppressive therapy.Joint Bone Spine. 2003 Feb;70(1):40-5. doi: 10.1016/s1297-319x(02)00009-x. Joint Bone Spine. 2003. PMID: 12639616
-
Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women.J Rheumatol. 1999 Jun;26(6):1280-4. J Rheumatol. 1999. PMID: 10381043
-
Steroid-induced osteoporosis--a cause for concern?Malays J Pathol. 1997 Jun;19(1):27-33. Malays J Pathol. 1997. PMID: 10879239 Review. No abstract available.
-
Prevalence and Risk Factors of Reduced Bone Mineral Density in Systemic Lupus Erythematosus Patients: A Meta-Analysis.Biomed Res Int. 2019 Feb 20;2019:3731648. doi: 10.1155/2019/3731648. eCollection 2019. Biomed Res Int. 2019. PMID: 30915352 Free PMC article.
Cited by
-
Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.Osteoporos Int. 2015 Feb;26(2):459-67. doi: 10.1007/s00198-014-2860-9. Epub 2014 Aug 22. Osteoporos Int. 2015. PMID: 25146092
-
Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression.PLoS One. 2018 Jun 13;13(6):e0196113. doi: 10.1371/journal.pone.0196113. eCollection 2018. PLoS One. 2018. PMID: 29897913 Free PMC article.
-
Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.Drugs. 2001;61(5):685-712. doi: 10.2165/00003495-200161050-00013. Drugs. 2001. PMID: 11368289 Review.
-
Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus.Clin Rheumatol. 2009 Jan;28(1):65-70. doi: 10.1007/s10067-008-0984-z. Epub 2008 Aug 1. Clin Rheumatol. 2009. PMID: 18670734
-
Bisphosphonates for the prevention and treatment of osteoporosis in patients with rheumatic diseases: a systematic review and meta-analysis.PLoS One. 2013 Dec 6;8(12):e80890. doi: 10.1371/journal.pone.0080890. eCollection 2013. PLoS One. 2013. PMID: 24324644 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical